SCHEMBL1334539

SCHEMBL1334539

C[C@H]1CC[C@H](Nc2ncc(-c3ccc(OCC#N)cc3)c(OCC3CCOC3)n2)CC1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CNR1 P21554 1/20 0.41
CNR2 P34972 1/20 0.41
XDH P47989 1/20 0.37
KDM4E B2RXH2 1/20 0.36
ALDH1A1 P00352 1/20 0.36
MAPT P10636 1/20 0.36
HPGD P15428 1/20 0.36
RAB9A P51151 1/20 0.36
HSD17B10 Q99714 1/20 0.36
PDE10A Q9Y233 1/20 0.36
GRM5 P41594 1/20 0.36
JAK2 O60674 1/20 0.35
JAK1 P23458 1/20 0.35
TYK2 P29597 1/20 0.35
STAT3 P40763 1/20 0.35
JAK3 P52333 1/20 0.35
KCNH2 Q12809 1/20 0.34
PIK3C3 Q8NEB9 1/20 0.34
CHEK1 O14757 1/20 0.34
KDM1A O60341 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1334535 1.00 CNR1 (0.41) CNR1CNR2XDHKDM4EALDH1A1
SCHEMBL1333272 0.96 KDM4E (0.37) CNR1CNR2KDM4EALDH1A1MAPT
SCHEMBL1333274 0.96 KDM4E (0.37) CNR1CNR2KDM4EALDH1A1MAPT
SCHEMBL1334460 0.91 GRM5 (0.39) KDM4EALDH1A1MAPTHPGDRAB9A
SCHEMBL1334461 0.91 GRM5 (0.39) KDM4EALDH1A1MAPTHPGDRAB9A
SCHEMBL1033087 0.89 GRM5 (0.38) CNR1KDM4EALDH1A1MAPTHPGD
SCHEMBL1033086 0.89 GRM5 (0.38) CNR1KDM4EALDH1A1MAPTHPGD
SCHEMBL1332925 0.87 CNR1 (0.37) CNR1CNR2KDM4EALDH1A1MAPT
SCHEMBL1334218 0.87 CNR1 (0.37) CNR1CNR2KDM4EALDH1A1MAPT
SCHEMBL1334221 0.87 CNR1 (0.37) CNR1CNR2KDM4EALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8513242-B2 Pyrimidine compounds and methods of making and using same CYSTIC FIBROSIS FOUNDATION THERAPEUTICS, INC. (US) 2013-08-20 US disclosed
US-20110281873-A1 Pyrimidine Compounds and Methods of Making and Using Same CYSTIC FIBROSIS FOUNDATION 2011-11-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110281873-A1 Pyrimidine Compounds and Methods of Making and Using Same CFTR, GPR17, TYMS CNR1 1055/4885CNR2 836/4885XDH 515/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.